Eli Lilly and Co
November trading, Berkshire’s cash hoard, Big Tech’s ad revenue and more in Morning Squawk
A trader works on the floor of the New York Stock Exchange on Oct. 30, 2025 in New York. Angela Weiss | AFP | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. November […]
Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied. From fresh competition to new uses, the market is quickly vaulting into a new stage of […]
Read More
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to […]
Read More
Samsung building facility with 50,000 Nvidia GPUs to automate chip manufacturing
Jensen Huang, chief executive officer of Nvidia Corp., during the keynote address at the Nvidia GTC (GPU Technology Conference) in Washington, DC, US, on Tuesday, Oct. 28, 2025. Kent Nishimura | Bloomberg | Getty Images Korean semiconductor giant Samsung said on Thursday that it plans to buy and deploy a cluster of 50,000 Nvidia graphic […]
Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]
Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]
Read More
Stocks making the biggest moves premarket: Alphabet, Microsoft, Meta Platforms, Eli Lilly, Merck & more
Check out the companies making headlines before the bell: Alphabet — The search giant jumped more than 7% after strong results that were boosted by revenue from Google Cloud and YouTube advertising. Alphabet earned $3.10 per share, on an adjusted basis, more than the $2.33 per share expected by analysts polled by LSEG. Revenue of […]
Read More
Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Denmark’s Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the fast-growing and competitive weight-loss drug market. Novo Nordisk, the company behind blockbuster weight loss drug Wegovy and diabetes […]
Read More
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster […]
Read More
Market moves after the Fed rate cut — plus, two price target hikes on big-name stocks
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The S & P 500 flipped between positive and negative Wednesday afternoon after Federal Reserve Chairman Jerome Powell said a December interest rate cut was […]
Read More